Table 4.
Determination of diagnostic capabilities.
| AUC | 95% CI | Sensitivity | Specificity | Positive predictive value | Negative predictive value | |
|---|---|---|---|---|---|---|
| ANO1 | 0.80 | 0.73–0.88 | 64.2% | 88.1% | 91.2% | 56.0% |
| CEA | 0.67 | 0.71–0.87 | 69.5% | 30.6% | 71.6% | 48.6% |
| CA199 | 0.73 | 0.65–0.82 | 77.8% | 40.5% | 65.8% | 42.3% |
| CA724 | 0.79 | 0.58–0.77 | 81.5% | 54.8% | 77.6% | 60.5% |
| ANO1 + CEA | 0.83 | 0.76–0.90 | 77.8% | 76.2% | 86.3% | 64.0% |
| ANO1 + CA199 | 0.87 | 0.82–0.94 | 81.5% | 76.2% | 86.8% | 68.1% |
| ANO1 + CA724 | 0.90 | 0.85–0.95 | 83.9% | 80.8% | 89.4% | 72.3% |
| CEA + CA199 + CA724 | 0.84 | 0.77–0.91 | 82.7% | 59.5% | 79.8% | 64.1% |
| ANO1 + CEA + CA199 + CA724 | 0.92 | 0.87–0.96 | 87% | 81% | 89.8% | 77.2% |
Summarized the AUC, sensitivity, specificity, positive predictive value and negative predictive value of ANO1 mRNA, CEA, CA199 and CA724 for the diagnosis of GISTs.